Correlation between drug use intensity of carbopenems and drug resistance of common gram negative bacilli
SHEN Xiaohong1 LYU Meiyan1 WANG Lizhi1 XU Xiangwei2
1.Department of Clinical Laboratory, Yongkang First People′s Hospital, Zhejiang Province, Yongkang 321300, China;
2.Department of Pharmacy, Yongkang First People′s Hospital, Zhejiang Province, Yongkang 321300, China
Abstract：Objective To analyze the changes of defined daily doses of carbapenems antibacterial agents and the changes of main gram negative bacilli of carbapenems resistant drugs, and the relationship between them. Methods The use conditions of carbapenems antibacterial agents in Yongkang First People′s Hospital of Zhejiang Province (“our hospital” for short) from January 2014 to January 2017 were collected by hospital information system, and the resistant rate of gram negative bacilli for carbapenems was calculated by WHONET 5.4 software, and the correlation analysis was performed. Results The amount of carbapenems antibacterial agents in our hospital was increasing year by year, among which, the used number, consumption sum and defined daily doses of Meropenem increased rapidly. The total bacteria inspection results of our hospital were increased year by year, among the several major gram negative bacilli, the growth rate of Acinetobacter baumannii detection among 4 years had highly statistically significant difference (P ＜ 0.01), as well as, Acinetobacter baumannii had a significant growth resistance to Meropenem and Imipenem/Cilastatin Sodium (P ＜ 0.05), Klebsiella pneumonia had a significant growth resistance to Meropenem (P ＜ 0.01). Furthermore, the resistance rate of Acinetobacter baumannii and Klebsiella pneumoniae for Meropenem was positively correlated with the defined daily doses of Meropenem (P ＜ 0.05). Conclusion Along with the application of carbapenems antibacterial agents and the increased test number of main gram negative bacilli year by year, there is some correlation between defined daily doses of carbapenems and the increase of some drug-resistance bacteria. It is necessary to strengthen the management of carbapenems, and control the production of drug-resistant bacteria.
沈晓红1 吕美艳1 王丽之1 徐象威2. 碳青霉烯类药物使用强度与常见革兰阴性杆菌耐药相关性[J]. 中国医药导报, 2019, 16(18): 109-112.
SHEN Xiaohong1 LYU Meiyan1 WANG Lizhi1 XU Xiangwei2. Correlation between drug use intensity of carbopenems and drug resistance of common gram negative bacilli. 中国医药导报, 2019, 16(18): 109-112.
[1] 贾天野，汤一苇，孙强正，等.碳青霉烯类抗生素耐药菌的治疗选择[J].传染病信息，2014（5）：315-318.
[2] Moore LS，Freeman R，Gilchrist MJ，et al. Homogeneity of antimicrobial policy，yet heterogeneity of antimicrobial resistance：antimicrobial non-susceptibility among 108 717 clinical isolates from primary，secondary and tertiary care patients in London [J]. J Antimicrob Chemother，2014，69（12）：3409-3422.
[3] Eraksoy H. Carbapenem-Resistant Pseudomonas aeruginosa [J]. Klimik Dergisi，2015，27（2）：37.
[4] 国家卫生计生委合理用药专家委员会，全国细菌耐药监测网.2015年国细菌耐药监测报告[J].中国执业药师，2016（3）：3-8.
[5] Bartsch SM，Huang SS，Wong KF，et al. Impact of Delays between the Clinical and Laboratory Standards Institute（CLSI）and the Food and Drug Administration（FDA）Revising Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae（CRE）[J]. J Clin Microbiol，2016，54（11）：2757-2762.
[6] 陈新谦，金有豫，汤光.新编药物学[M].17版.北京：人民卫生出版社，2011.
[7] Li B，Xu XH，Zhao ZC，et al. High prevalence of metallo-β-lactamase among carbapenem-resistant Klebsiella pneumoniae in a teaching hospital in China [J]. Can J Microbiol，2014，60（10）：691-695.
[8] Qureshi ZA，Hittle LE，O'Hara JA，et al. Colistin-Resistant Acinetobacter baumannii：Beyond Carbapenem Resistance [J]. Clin Infect Dis，2015，60（9）：1295-1303.
[9] 卫生部医政司.2012年全国抗菌药物临床应用专项整治活动方案（节选）[J].中国社区医师：医学专业，2012， 14（8）：407.
[10] 杨小强.我国抗菌药物临床应用监测网工作现状与发展[J].中华临床感染病杂志，2016，9（5）：388-392.
[11] Zhanel GG，Simor AE，Vercaigne L，et al. Imipenem and meropenem：Comparison of in vitro activity，pharmacokinetics，clinical trials and adverse effects [J]. Can J Infect Dis，2016，9（4）：215-228.
[12] 刘茂昌，葛苗苗，陈渝军，等.美罗培南与亚胺培南/西司他汀治疗重症感染疗效与安全性的Meta分析[J].中国抗生素杂志，2014，39（10）：785-790.
[13] Nakane T，Tamura K，Hino M，et al. Cefozopran，meropenem，or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients：A multicenter prospective randomized trial [J]. J Infect Chemother，2015，21（1）：16-22.
[14] 李志业，冀建伟，邢玲.美罗培南持续静脉泵入治疗化脓性脑膜炎的效果分析[J].中国实用神经疾病杂志，2016， 19（18）：128.
[15] Pournaras S，Koumaki V，Gennimata V，et al. In Vitro Activity of Tigecycline Against Acinetobacter baumannii：Global Epidemiology and Resistance Mechanisms [J]. Adv Exp Med Biol，2016，897：1-14.
[16] 孟芝君.2012-2014年我院鲍曼不动杆菌临床分布与耐药性分析[J].中国药物与临床，2016，16（7）：980-982.
[17] 福泉，包丽丽，张迪，等.2011至2015年某院临床分离的鲍曼不动杆菌耐药性变迁及标本分布[J].中国实验诊断学，2016，20（11）：1878-1880.
[18] 赵强，郭玲，叶丽艳，等.耐碳青霉烯类肺炎克雷伯菌医院感染流行特征分析[J].中华医院感染学杂志，2016， 26（21）：4809-4811.
[19] Zhou C，Chen X，Liwen WU，et al. Distribution of drug-resistant bacteria and rational use of clinical antimicrobial agents [J]. Exp Ther Med，2016，11（6）：2229-2232.
[20] Marshall BM，Robleto E，Dumont T，et al. The frequency of antibiotic-resistant bacteria in homes differing in their use of surface antibacterial agents [J]. Curr Microbiol，2012， 65（4）：407-415.
[21] Nordmann P. Gram-negative bacteriae with resistance to carbapenems [J]. Med Sci（Paris），2010，26（11）：950-959.
[22] Hua Y，Qu F，Shan B，et al. Detection of the mcr-1 Colistin Resistance Gene in Carbapenem-Resistant Enterobacteriaceae from Different Hospitals in China [J]. Antimicrob Agents Chemother，2016，60（8）：5033-5035.
2019, Vol. 16 
京公网安备 11010502046598号